|
Volumn 22, Issue 2, 2008, Pages 92-99
|
The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy.
a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
COLORING AGENT;
DIAGNOSTIC AGENT;
INDOCYANINE GREEN;
MONOCLONAL ANTIBODY;
VASCULOTROPIN A;
AGED;
ARTICLE;
CASE REPORT;
CHOROID;
DRUG ANTAGONISM;
FEMALE;
FLUORESCENCE ANGIOGRAPHY;
HUMAN;
INJECTION;
MALE;
MIDDLE AGED;
MULTIMODALITY CANCER THERAPY;
OPTICAL COHERENCE TOMOGRAPHY;
PATHOLOGY;
PATHOPHYSIOLOGY;
PERIPHERAL VASCULAR DISEASE;
PHOTOCHEMOTHERAPY;
PHYSIOLOGY;
PILOT STUDY;
RETROSPECTIVE STUDY;
TREATMENT OUTCOME;
VASCULARIZATION;
VISUAL ACUITY;
VITREOUS BODY;
AGED;
AGED, 80 AND OVER;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
CHOROID;
COLORING AGENTS;
COMBINED MODALITY THERAPY;
FEMALE;
FLUORESCEIN ANGIOGRAPHY;
HUMANS;
INDOCYANINE GREEN;
INJECTIONS;
MALE;
MIDDLE AGED;
PERIPHERAL VASCULAR DISEASES;
PHOTOCHEMOTHERAPY;
PILOT PROJECTS;
RETROSPECTIVE STUDIES;
TOMOGRAPHY, OPTICAL COHERENCE;
TREATMENT OUTCOME;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
VISUAL ACUITY;
VITREOUS BODY;
|
EID: 52149108320
PISSN: 10118942
EISSN: None
Source Type: Journal
DOI: 10.3341/kjo.2008.22.2.92 Document Type: Article |
Times cited : (60)
|
References (0)
|